NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.
By R. Stupp, Eric T Wong, A. Kanner, D. Steinberg, H. Engelhard, V. Heidecke, E. Kirson, S. Taillibert, F. Liebermann, V. Dbalý and 25 more. European Journal of Cancer, 2012
831 citations recorded by the source corpus.
PURPOSE NovoTTF-100A is a portable device delivering low-intensity, intermediate frequency electric fields via non-invasive, transducer arrays. Tumour Treatment Fields (TTF), a completely new therapeutic modality in cancer treatment, physically interfere with cell division. METHODS Phase III trial of chemotherapy-free treatment of NovoTTF (20-24h/day) versus active chemotherapy in the treatment of patients with recurrent glioblastoma. Primary end-point was improvement of overall survival. RESULTS Patients (median age 54 years (range 23-80), Karnofsky performance status 80% (range 50-100) were randomised to TTF alone (n=120) or active chemotherapy control (n=117). Number of prior treatments was two (range 1-6). Median survival was 6.6 versus 6.0 months (hazard ratio 0.86 [95% CI 0.66-1.12]; p=0.27), 1-year survival rate was 20% and 20%, progression-free survival rate at 6 months was 21.4% and 15.1% (p=0.13), respectively in TTF and active control patients. Responses were more common in the TTF arm (14% versus 9.6%, p=0.19). The TTF-related adverse events were mild (14%) to moderate (2%) skin rash beneath the transducer arrays. Severe adverse events occurred in 6% and 16% (p=0.022) of patients treated with TTF and chemotherapy, respectively. Quality of life analyses favoured TTF therapy in most domains. CONCLUSIONS This is the first controlled trial evaluating an entirely novel cancer treatment modality delivering electric fields rather than chemotherapy. No improvement in overall survival was demonstrated, however efficacy and activity with this chemotherapy-free treatment device appears comparable to chemotherapy regimens that are commonly used for recurrent glioblastoma. Toxicity and quality of life clearly favoured TTF.
Subfields: Artificial Intelligence, Computational Theory and Mathematics, Hardware and Architecture
View Paper: https://www.semanticscholar.org/paper/38bee15a0bd6e2602ddd019195813f826b5c9124
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- M. Davis
- P. Delgado-López
- M. Brada
- E. Corrales-García
- M. Bent
- S. Taillibert
- A. Kanner
- G. Pentheroudakis
Citations in the corpus
- Survival in glioblastoma: a review on the impact of treatment modalities (2016, background): “A phase III trial demonstrated that TTF had equivalent efficacy to chemotherapy without the typical and dangerous side effects of cyto-toxicity and that it permitted better quality of life [25].”
- High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, methodology): “Applying alternating electric fields—tumour-treating fields (TTFs)—using a batterypowered device connected to electrodes placed on the patient’s scalp—was compared with physicians’ choice of chemotherapy in a randomised trial in recurrent disease [58].”
- Glioblastoma: Overview of Disease and Treatment (2016, background): “6 October 2016 • Supplement to Volume 20, Number 5 • Clinical Journal of Oncology Nursing equivalent survival with fewer side effects and significantly less gastrointestinal, hematologic, and infectious adverse events (Stupp et al., 2012).”
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial (2017, background): “Blood and lymphatic system disordersa 59 (13) 23 (11)”
- Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. (2015, background): “Duration of treatment with TTFields, median (range), mo 9 (1-58) 9 (1-58)”